This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The ideological divide in confidence in science and participation in medical research
Scientific Reports Open Access 04 February 2021
-
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Journal of Hematology & Oncology Open Access 29 October 2008
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
De Angelis C. et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 351, 1250–1251 (2004).
De Angelis, C. et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 352, 2436–2438 (2005).
Karlberg, J. P. E. Globalization of sponsored clinical trials. Nature Rev. Drug Discov. 1 May 2008 (doi:10.1038/nrd2441-c1).
Thiers, F. A., Sinskey, A. J. & Berndt, E. R. Trends in the globalization of clinical trials. Nature Rev. Drug Discov. 7, 13–14 (2008).
Heron, M. Deaths: leading causes for 2004. Natl Vital Stat. Rep. 56, 1–96 (2007).
IMS Health. Leading Therapy Classes by Global Pharmaceutical sales, 2006. IMS Health web site [online], (2007).
US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. [online], (2007).
IMS Health. Leading products by Global Pharmaceutical Sales, 2006. IMS Health web site [online], (2007).
Narayan, K. M. V. et al. Lifetime risk for diabetes mellitus in the United States. JAMA 290, 1884–1990 (2003).
Mokdad, A. H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76–79 (2003).
Melnikova, I. & Wages, D. Anti-obesity therapies. Nature Rev. Drug Discov. 5, 369–370 (2006).
Acknowledgements
This study could not have been completed without the implementation of the International Committee of Medical Journal Editors policy and the existence of the ClinicalTrials.gov clinical trials register.
Author information
Authors and Affiliations
Supplementary information
Supplementary information S1 (box)
Analysis set and analysis (PDF 98 kb)
Supplementary information S2 (table)
Ranking of the top 40 therapeutic/disease areas (PDF 191 kb)
Rights and permissions
About this article
Cite this article
Karlberg, J. Trends in disease focus of drug development. Nat Rev Drug Discov 7, 639–640 (2008). https://doi.org/10.1038/nrd2618
Issue Date:
DOI: https://doi.org/10.1038/nrd2618
This article is cited by
-
The ideological divide in confidence in science and participation in medical research
Scientific Reports (2021)
-
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Journal of Hematology & Oncology (2008)